DE69907418D1 - Verwendung von makroliden zur behandlung von glaukom - Google Patents

Verwendung von makroliden zur behandlung von glaukom

Info

Publication number
DE69907418D1
DE69907418D1 DE69907418T DE69907418T DE69907418D1 DE 69907418 D1 DE69907418 D1 DE 69907418D1 DE 69907418 T DE69907418 T DE 69907418T DE 69907418 T DE69907418 T DE 69907418T DE 69907418 D1 DE69907418 D1 DE 69907418D1
Authority
DE
Germany
Prior art keywords
macrolides
treating glaucoma
compounds
glaucoma
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69907418T
Other languages
English (en)
Other versions
DE69907418T2 (de
Inventor
Shozo Sakuma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP1955A external-priority patent/AUPP195598A0/en
Priority claimed from AUPP2992A external-priority patent/AUPP299298A0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Publication of DE69907418D1 publication Critical patent/DE69907418D1/de
Application granted granted Critical
Publication of DE69907418T2 publication Critical patent/DE69907418T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
DE69907418T 1998-02-23 1999-02-17 Verwendung von makroliden zur behandlung von glaukom Expired - Fee Related DE69907418T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP1955A AUPP195598A0 (en) 1998-02-23 1998-02-23 New use
AUPP2992A AUPP299298A0 (en) 1998-04-16 1998-04-16 New use
PCT/JP1999/000681 WO1999042104A1 (en) 1998-02-23 1999-02-17 Use of macrolide compounds for treating glaucoma

Publications (2)

Publication Number Publication Date
DE69907418D1 true DE69907418D1 (de) 2003-06-05
DE69907418T2 DE69907418T2 (de) 2003-11-13

Family

ID=25645716

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69907418T Expired - Fee Related DE69907418T2 (de) 1998-02-23 1999-02-17 Verwendung von makroliden zur behandlung von glaukom

Country Status (9)

Country Link
US (1) US6384073B1 (de)
EP (1) EP1056454B1 (de)
JP (1) JP2002503692A (de)
AT (1) ATE238792T1 (de)
DE (1) DE69907418T2 (de)
DK (1) DK1056454T3 (de)
ES (1) ES2192832T3 (de)
PT (1) PT1056454E (de)
WO (1) WO1999042104A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7265150B1 (en) * 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US7338976B1 (en) * 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
EP1227859B1 (de) * 1999-11-12 2006-08-09 Alcon, Inc Verwendung von neurophilin liganden zur behandlung von augenerkrankungen
GB0012383D0 (en) * 2000-05-22 2000-07-12 Novartis Ag Organic compounds
WO2003061519A2 (en) * 2002-01-18 2003-07-31 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
WO2007011880A2 (en) 2005-07-18 2007-01-25 Minu, L.L.C. Enhanced ocular neuroprotection/neurostimulation
US7592330B2 (en) * 2005-08-08 2009-09-22 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
WO2008042216A2 (en) 2006-09-28 2008-04-10 Follica, Inc. Methods, kits, and compositions for generating new hair follicles and growing hair
KR20090094090A (ko) * 2006-12-28 2009-09-03 리머릭 바이오파르마 인코오포레이티드 치료를 위한 방법 및 조성물
WO2008127746A1 (en) 2007-01-10 2008-10-23 Board Of Regents The University Of Texas System Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
MX2010001141A (es) * 2007-07-31 2010-03-01 Limerick Biopharma Inc Analogos fosforiladosde pirona y metodos.
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
WO2012118863A1 (en) * 2011-02-28 2012-09-07 The Schepens Eye Research Institute, Inc. Therapies that target autoimmunity for treating glaucoma and optic neuropathy
US10428331B2 (en) 2014-01-16 2019-10-01 Musc Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
EP0581959B1 (de) * 1991-04-26 2001-01-17 Fujisawa Pharmaceutical Co., Ltd. Verwendung von makrolid-verbindungen gegen augenerkrankungen
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
WO1997031020A1 (en) * 1996-02-22 1997-08-28 The General Hospital Corporation METHODS AND COMPOSITIONS FOR ENHANCING CELLULAR RESPONSE TO TGF-β LIGANDS
US5994388A (en) * 1997-03-18 1999-11-30 The Children's Medical Center Corporation Cytochalasin and isoindolinone derivatives as inhibitors of angiogenesis

Also Published As

Publication number Publication date
US6384073B1 (en) 2002-05-07
WO1999042104A1 (en) 1999-08-26
ES2192832T3 (es) 2003-10-16
EP1056454B1 (de) 2003-05-02
JP2002503692A (ja) 2002-02-05
DK1056454T3 (da) 2003-08-18
EP1056454A1 (de) 2000-12-06
PT1056454E (pt) 2003-08-29
ATE238792T1 (de) 2003-05-15
DE69907418T2 (de) 2003-11-13

Similar Documents

Publication Publication Date Title
DE69907418D1 (de) Verwendung von makroliden zur behandlung von glaukom
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
DE69521620D1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
ATE292971T1 (de) (s,s)-reboxetin zur behandlung von peripheren neuropathien
ATE198708T1 (de) Verwendung von makrolid-verbindungen gegen augenerkrankungen
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE59409832D1 (de) Pflaster zur behandlung von nagelmykosen
DE69943287D1 (de) Antibiotische zusammensetzung, die moxifloxacin enthält, zur behandlung von augen
PE14199A1 (es) Agonistas de 5-ht1f
DE59409312D1 (de) Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
ES2080297T3 (es) Derivados 17-g(b)-sustituido-4-aza-5g(a)-androstan-3-ona y procedimiento de preparacion de estos.
DE69835536D1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
ATE271390T1 (de) Verwendung von azithromycin zur topischen behandlung von augeninfektionen
PT932613E (pt) Expressao de bloqueio de factoes de virulencia em s. aureus
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE266027T1 (de) Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
ATE244008T1 (de) Verwendung von makroliden zur behandlung von akuten lungenverletzungen
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
MXPA04001255A (es) Uso de compuesto para el tratamiento de condiciones que resultan de lesion al nervio corneo despues de lasik y otras cirugias oculares o trauma.
DE69916013D1 (de) Vorderkammerimplantat zur behandlung des phaken auges
ATE271384T1 (de) Arylnitron therapeutische mittel zur behandlung von entzündlichen darmerkrankungen
DE69926996D1 (de) Verwendung von riluzol zur behandlung der retinalischemie
DE69022027T2 (de) 2-Alkyl-3-benzoylbenzofurane zur Behandlung von Herzarrhythmia.
DE60012163D1 (de) Verwendung von ap-1 aktivatoren zur behandlung von glaukom und erhöhtem augenblutdruck

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASTELLAS PHARMA INC., TOKIO/TOKYO, JP

8339 Ceased/non-payment of the annual fee